Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04176848
Title CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

CFI-400945 + Durvalumab

Age Groups: adult | senior
Covered Countries CAN

Facility Status City State Zip Country Details
Juravinski Cancer Centre at Hamilton Health Sciences Not yet recruiting Hamilton Ontario L8V 5C2 Canada Details
Kingston Health Sciences Centre Recruiting Kingston Ontario K7L 2V7 Canada Details
Ottawa Hospital Research Institute Recruiting Ottawa Ontario K1H 8L6 Canada Details
University Health Network Recruiting Toronto Ontario M5G 2M9 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field